Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Winter;6(2):90-96.

Management of metastatic castration-resistant prostate cancer

Emmanuel S Antonarakis  1
Affiliations

Management of metastatic castration-resistant prostate cancer

Emmanuel S Antonarakis. Eur Urol Rev. 2011 Winter.

Abstract

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the last 2 years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel, and abiraterone acetate), and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimize delivery of care and long term outcomes in men with advanced CRPC.

Keywords: MDV3100; abiraterone; cabazitaxel; castration-resistant prostate cancer; denosumab; drug development; ipilimumab; novel therapies; orteronel; sipuleucel-T.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr Antonarakis has served as an advisor/consultant for Sanofi-Aventis.

Figures

Figure 1
Figure 1. The therapeutic landscape for prostate cancer in 2011
Abbreviations: ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer
Figure 2
Figure 2. The androgen signaling axis in CRPC
Abbreviations: CRPC, castration-resistant prostate cancer; AR, androgen receptor; A; androgen; HSP, heat shock protein; CoAct; transcriptional coactivators.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520. - PubMed
    1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764. - PubMed
    1. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20:241–246. - PMC - PubMed

LinkOut - more resources